GE HealthCare (GEHC)
Health Care · medical devices and diagnostics · NASDAQ
GE HealthCare is a leading global medical technology provider delivering advanced diagnostic imaging, clinical systems, and intelligent digital solutions to healthcare providers worldwide.
What GE HealthCare does
GE HealthCare is a global medical technology company that develops, manufactures, and markets a broad range of medical systems, diagnostic imaging products, and digital healthcare solutions. The company provides essential equipment and services used in the diagnosis, treatment, and monitoring of patients, as well as pharmaceutical diagnostics. Its operations are focused on integrating hardware with software, artificial intelligence, and data analytics to improve clinical outcomes and operational efficiency for healthcare providers.
Themes: medical imaging, digital health, artificial intelligence in healthcare, precision medicine, medical diagnostics, clinical software platforms, patient monitoring, healthcare IT infrastructure
Fundamentals
- Price$74.19 as of 2026-08-24 close
- Market cap$33.7B as of 2026-08-24
- 1-year return-1.4% 2025-08-22 close $75.22 → 2026-08-24 close $74.19
- P/E17.06 as of 2026-08-24
- Net margin+9.3% as of 2026-08-24
- Gross margin+39.5% as of 2026-08-24
- ROE+18.9% as of 2026-08-24
- Debt / equity0.92 as of 2026-08-24
- Revenue growth (YoY)+6.5% as of 2026-08-24
- Revenue CAGR (3y)+4.0% SEC XBRL
- Beta1.08 as of 2026-08-24
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.2%; at least 3 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How GEHC compares in its sector
- price-to-earnings ratiobottom 25% 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GEHC is not currently in any published Top 10 list. Its scores are below.
Long-term score
48.1 #932 of 1,605 scored · #108 of 195 in Health Care
Valuation 69th (price to earnings 17.1, price to book 3.2) and profitability 59th (return on equity 18.9%, operating margin 12.9%); weakest is financial health (33rd, free cash flow margin 7.4%, debt to equity 0.9).
Short-term score
52.1 #554 of 1,698 scored · #115 of 236 in Health Care
Trend 71st: the price is 8% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; momentum 66th: MACD momentum is positive; weakest is volume and participation 27th: trading volume is unusually light — only about 50% of its 30-day average.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, GEHC's dividend was covered by reported results (earnings payout 3%, free-cash-flow payout 4%). This describes past coverage, not a forecast.
- Earnings payout3% dividends / net income
- Free-cash-flow payout4% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How GE HealthCare looks technically
GE HealthCare (GEHC) is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 92 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago. It is 17.4% below its highest point of the past year. Trading volume is unusually light — only about 50% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $66.85 | $66.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $73.03 | $73.03 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 92 trading days ago — a "death cross", a bearish long-term signal | 92 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.6% above | +1.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control | 29.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($69.58 to $75.65) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 75.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $89.77 | $89.77 |
|---|---|---|
| From the 52-week high | it is 17.4% below its 52-week high (its highest price of the past year) | -17.4% |
| Above the 52-week low | it is 26.3% above its 52-week low (its lowest price of the past year) | +26.3% |
| Below the 52-week high | it is 17.4% below its highest point of the past year | 17.4% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $94.80 (set on 2025-02-13) | $94.80 |
| Given back of the 52-week move | over the past year its closes ranged ($59.48 to $88.16), and it has recovered around half of its fall from last year’s high — 51% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $77.21 to $78.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 51.3% |
| From the all-time high | it is 21.7% below its all-time high | -21.7% |
| Nearest price level | it is trading 0.6% above a support level at $73.78 — a price it turned at three times since 2025-06-11, most recently on 2026-03-26. Since 2024-08-26 it has 5 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $53.50 (set on 2023-01-04) | $53.50 |
| Above the all-time low | it is 38.7% above its all-time low | +38.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 57th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.89 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.89 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $66.68 and $76.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $66.68 – $71.72 – $76.76 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges above its 200-day average price (1.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 50% of its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 15 sessions ago and has not traded back through the level it left behind at 68.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 2.8% gap down opened on 2026-07-14 has been "filled" 27 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 27 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 19.1 percentage points (the stock gained 22.5% while the market gained 3.3%) | +19.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 13.1 percentage points (the stock gained 15.5% while the market gained 2.4%) | +13.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 22.8 percentage points (the stock lost 11.7% while the market gained 11.1%) | -22.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 19.7 percentage points (the stock lost 1.4% while the market gained 18.3%) | -19.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.0% of the share price, which is taken to mean a barrier that gives way easily. | +17.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $69.39 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $69.00 — a volume-weighted average of daily closes over 23 sessions, not a true tick-by-tick VWAP. | +7.5% |
Price levels it has turned at before
GEHC last closed at $74.19 on 2026-08-24. Since 2024-08-26 it has turned at 5 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $73.78 | Support | 0.6% below the last close | turned there three times · 2025-06-11 to 2026-03-26 |
| $72.10 | Support | 2.8% below the last close | turned there five times · 2025-04-30 to 2026-07-29 |
| $76.38 | Resistance | 3.0% above the last close | turned there 7 times · 2024-12-20 to 2026-04-17 |
| $78.09 | Resistance | 5.3% above the last close | turned there five times · 2025-05-12 to 2026-01-29 |
| $69.26 | Support | 6.7% below the last close | turned there 10 times · 2025-05-22 to 2026-03-30 |
| $80.12 | Resistance | 8.0% above the last close | turned there four times · 2024-11-22 to 2025-10-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · lagging the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.74 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$82.50 range $70.00 – $96.00; median $83.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GEHC
- Consensus EPS estimate$1.20 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Highly competitive markets and pressure on healthcare reimbursement rates.","Geopolitical instability, including trade and tariff policies and operations in China.","Operational risks related to complex global supply chains and information technology/cybersecurity security."]
What changed in the latest 10-Q
AI-assisted comparison of GEHC's 10-Q filed 2026-04-29 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Added disclosure of U.S. Supreme Court ruling in February 2026 regarding IEEPA and tariff authority (newer filing 2026-04-29)
- Added disclosure of U.S. Customs and Border Protection announcement in April 2026 regarding administrative process for tariff refunds (newer filing 2026-04-29)
- Added statement that tariffs materially impacted Operating income by approximately $90 million and cash flows by approximately $110 million for Q1 2026 (newer filing 2026-04-29)
- Added paragraph discussing company investments in China to address clinical needs, localization, and commercial infrastructure (newer filing 2026-04-29)
- Removed:
- Removed reference to March 2024 China government stimulus program ('2024 stimulus') and discussion of short-term delays in province planning and customer purchasing decisions (older filing 2025-10-29)
- Removed statement about expecting delays to continue impacting orders and revenues in near term with inability to predict exact duration or magnitude (older filing 2025-10-29)
- Removed disclosure of $241 million in assets as of September 30, 2025 related to Russia and Ukraine; replaced with $194 million as of March 31, 2026 (newer filing 2026-04-29)
- Removed disclosure of $209 million in revenues from Russia/Ukraine customers for nine months ended September 30, 2025; replaced with $54 million for three months ended March 31, 2026 (newer filing 2026-04-29)
- Removed phrase 'will continue to do so' regarding licensing measures; replaced with 'is expected to continue to do so' (newer filing 2026-04-29)
- Removed phrase 'that any approvals we obtain will be on a timely basis, or' from licensing guarantee statement (newer filing 2026-04-29)
- Reworded:
- Changed period covered from 'three and nine months ended September 30, 2025 and 2024' to 'three months ended March 31, 2026 and 2025' (newer filing 2026-04-29)
- Changed reference from 'Annual Report on Form 10-K for the fiscal year ended December 31, 2024' to 'Annual Report on Form 10-K for the fiscal year ended December 31, 2025' (newer filing 2026-04-29)
- Changed segment organization disclosure from 'GE HealthCare's operations are organized' to 'As of March 31, 2026, GE HealthCare's operations are organized' (newer filing 2026-04-29)
- Changed tariff disclosure from 'Throughout 2025, the U.S. has imposed' to 'Starting in February 2025, the U.S. imposed' with additional detail on subsequent developments (newer filing 2026-04-29)
- Changed tariff mitigation language from 'we do not expect to be able to fully offset' to 'we do not expect that our mitigation actions will fully offset' (newer filing 2026-04-29)
- Changed Russia/Ukraine discussion from 'will continue to do so' to 'is expected to continue to do so' regarding implementation of licensing measures (newer filing 2026-04-29)
- Rephrased China market discussion to remove specific reference to 2024 stimulus program delays and replace with generalized discussion of competition and volume-based procurement (newer filing 2026-04-29)
- Changed guarantee language from 'There is no guarantee we will obtain all of the licenses for which we applied' to 'There is no guarantee we will obtain all of the licenses for which we apply' (newer filing 2026-04-29)
- Notes:
- The older filing text appears truncated at the end of the Russia/Ukraine section; comparison of final sentences is based on available text
- The newer filing text also appears truncated at the end of the provided excerpt
- Older filing covers nine-month period while newer filing covers three-month period, making some numerical comparisons not directly comparable
Risk Factors
- Added:
- Newer filing adds reference to 'changes to our business, operating, and leadership structure and related impacts' in forward-looking statements section
- Newer filing adds 'and conflicts in the Middle East' to describe international conflicts (expanding beyond Ukraine/Russia reference)
- Newer filing adds 'key material price volatility and availability' to risks mentioned
- Newer filing adds 'changes in or elimination of government subsidies' as a risk factor
- Newer filing adds 'increasing attention to sustainability matters' as a risk factor
- Newer filing adds 'or similar proceedings' after 'potential litigation, arbitration'
- Newer filing references Form 10-K for fiscal year ended December 31, 2025 (versus December 31, 2024 in older filing)
- Removed:
- Older filing includes 'changes to our business, operating, and leadership structure' language not clearly present in newer version's forward-looking statements
- Older filing separately lists 'the Russia and Ukraine conflict' in opening paragraph; newer version integrates into broader conflict reference
- Older filing mentions 'environmental, social, and governance matters'; newer filing changes this to 'increasing attention to sustainability matters'
- Older filing states 'and our general ability to comply with covenants under our debt instruments'; newer filing shortens to 'and the impact of complying with the covenants and other terms of our debt instruments'
- Reworded:
- Newer filing: 'key material price volatility' added alongside 'commodity price volatility' (older filing only mentioned 'commodity price volatility')
- Newer filing: Changes 'environmental, social, and governance matters' (older) to 'increasing attention to sustainability matters' (newer)
- Newer filing: Expands geopolitical conflicts description to explicitly include 'in other regions' beyond Ukraine/Russia and Middle East
- Newer filing: Modifies debt covenant language from 'our general ability to comply with covenants under our debt instruments, and any related effect on our business' to 'the impact of complying with the covenants and other terms of our debt instruments on our business'
- Newer filing changes 'key personnel' (older) to 'key talent' in talent retention risk
- Notes:
- The provided newer filing text appears truncated at the financial statements section and does not include the full Item 1A Risk Factors content, limiting assessment of detailed risk factor changes
- Comparison is primarily based on Forward-Looking Statements section rather than the full Risk Factors section due to truncation of newer filing
- Financial statement data presented in newer and older filings reflects different periods (Q1 2026 vs Q3 2025 and nine-month periods), making direct operational comparisons outside scope of this text comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days8 buys ($6M) · 0 sells — 8 buying insiders
Cluster buying: 8 different insiders reported open-market purchases (SEC code P) of GEHC within a 30-day window between 2026-04-30 and 2026-05-22. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-22. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GEHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 6 matched disclosures for GEHC from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding GEHC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 62,668,395
- Reported value $4,460,736,381
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GEHC had 19,385,482 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GEHC had 4.26% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.94 days to cover at the same settlement.
- Reported short interest (shares) 19,385,482
- Short interest (% of shares outstanding) 4.26%
- Prior settlement (shares) 18,451,068
- Reported change 5.06%
- Days to cover (reported) 2.94
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Siemens Healthineers (SMMNY)
- Philips (PHG)
- Canon Medical Systems
- Fujifilm Healthcare
- Hologic (HOLX)
- Medtronic (MDT)
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GEHC vs…
GE HealthCare is found in…
GEHC shows up in…
Frequently asked questions
What does GE HealthCare (GEHC) do?
GE HealthCare is a global medical technology company that develops, manufactures, and markets a broad range of medical systems, diagnostic imaging products, and digital healthcare solutions. The company provides essential equipment and services used in the diagnosis, treatment, and monitoring of patients, as well as pharmaceutical diagnostics.
What sector is GE HealthCare (GEHC) in?
GE HealthCare (GEHC) is classified in the Health Care sector. Its industry is medical devices and diagnostics. It trades on NASDAQ.
Does GEHC pay a dividend?
Yes — GE HealthCare (GEHC) pays a dividend, with an indicated yield of about 0.16% and at least 3 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are GE HealthCare's (GEHC) competitors?
Notable peers of GE HealthCare (GEHC) include Siemens Healthineers, Philips, Canon Medical Systems, Fujifilm Healthcare and Hologic. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in GEHC?
Yes — we hold 6 matched STOCK Act disclosures for GEHC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is GE HealthCare (GEHC) overbought or oversold right now?
GE HealthCare (GEHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GEHC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.